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This year marks the centennial of the devastating 1918 influenza A(H1N1) pandemic, which 
killed an estimated 50 million people worldwide. Prevention and control activities were 
limited in 1918 because global surveillance did not exist, influenza viruses were not yet 
discovered, and no influenza vaccines had been developed. Diagnostic tests for influenza 
were unavailable prior to isolation of influenza viruses in the 1930s, so spread of the 
pandemic virus was tracked by news reports of increased respiratory disease and related 
deaths. Establishment of the World Health Organization’s Global Influenza Surveillance 
Network in 1952 has contributed substantially to coordinated surveillance, vaccine 
development, and influenza vaccine strain selection.
Pandemic influenza vaccine was not available until the 1957 influenza A(H2N2) pandemic, 
so prevention and control efforts in 1918 relied on nonpharmaceutical interventions, 
including isolation and quarantine, social distancing, public gathering bans, school closures, 
and mask wearing. Treatment options were limited: antivirals were not available until the 
1968 influenza A(H3N2) pandemic; antibiotics for secondary bacterial infections had not yet 
been discovered; and organ supporting care strategies, other than supplemental oxygen, did 
not exist until the mid-1950s. While advances in influenza surveillance and availability of 
influenza vaccines have been increasingly effective, major gaps remain in the clinical 
response to seasonal influenza epidemics and pandemics.
During the 2009 influenza A(H1N1) pandemic, rapid antigen tests had suboptimal 
sensitivity in detecting the pandemic virus, frequently yielding false-negative results. 
Clinicians caring for hospitalized patients often had to wait at least one day for reverse 
Corresponding Author: Timothy M., Uyeki MD, MPH, MPP, Influenza Division, National Center for Immunization and Respiratory 
Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329 (tmu0@cdc.gov). 
Disclaimer: The views expressed hereinare those of the authors and do not necessarily reflect the official policy of the Centers for 
Disease Control and Prevention.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of 
Interest and none were reported.
HHS Public Access
Author manuscript
JAMA. Author manuscript; available in PMC 2019 August 01.
Published in final edited form as:
JAMA. 2018 August 28; 320(8): 755–756. doi:10.1001/jama.2018.8113.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
transcriptase-polymerase chain reaction testing results from a referral laboratory. Recently, 
molecular-based diagnostic tests (including rapid molecular assays) that can detect influenza 
viral nucleic acids in upper respiratory tract specimens with high sensitivity and specificity 
have become available in ambulatory and inpatient settings. How-ever, the molecular assays 
in use in clinical settings do not distinguish between seasonal and novel influenza A viruses 
of zoonotic origin and cannot specifically identify the next pandemic virus. Clinicians need 
to work closely with public health laboratories to monitor surveillance data. Development of 
tests based on next-generation sequencing technology may facilitate more accurate and 
timely identification of antigenically drifted seasonal influenza viruses, novel influenza A 
viruses, and viruses with known markers of antiviral resistance. Whether this would 
ultimately improve health out-comes would need to be determined.
Currently, antiviral treatment of influenza is focused on early initiation of monotherapy with 
one drug class, neuraminidase inhibitors (NAIs). Randomized clinical trials (RCTs) 
demonstrated shortened duration of fever and illness in outpatients with uncomplicated 
influenza who start treatment with the NAI oseltamivir within 2 days of symptom onset 
compared with placebo.1,2 A meta-analysis of RCTs involving adults and an observational 
study of high-risk children and adults reported reduced risk of hospitalization in outpatients 
treated with NAIs.1,3 However, enrolling hospitalized patients in RCTs of NAI treatment vs 
placebo has proved problematic, and challenges remain in identifying optimal end points.4 
Evidence for NAI effectiveness in hospitalized patients with influenza includes 
observational studies of variable quality. One meta-analysis of observational data from 29 
234 hospitalized patients (86% with laboratory-confirmed influenza A(H1N1) pdm09 virus 
infection) reported survival benefit in NAI-treated adults.5 However, not all observational 
studies of NAI treatment have reported benefit in hospitalized patients with influenza, and 
disagreement exists on the strength of the evidence base and the overall effectiveness of 
NAIs.6
Influenza virus resistance to antiviral drugs can emerge sporadically during or after antiviral 
treatment, particularly in severely immunocompromised patients. Oseltamivir-resistant 
influenza A(H1N1) viruses became prevalent worldwide between 2007 and early 2009. 
These viruses were replaced by the 2009 influenza A(H1N1) pandemic virus (now referred 
to as influenza A(H1N1)pdm09) which continues to circulate as a seasonal influenza A virus 
with sporadic detection of oseltamivir resistance. Given the potential for a widely circulating 
influenza virus with resistance to all NAIs, new and more effective antivirals, as well as tests 
to rapidly detect resistant viruses, are needed. Antivirals with different mechanisms of action 
than NAIs not only would treat NAI-resistant viruses but would also allow combination 
therapy of susceptible influenza virus infection. However, ensuring access to early antiviral 
treatment may be challenging: spot shortages of NAIs were reported this past winter in the 
United States. Because clinical benefit is greatest when NAI treatment is started soon after 
illness onset, sufficient supplies of antivirals must be available for immediate large-scale 
distribution in severe pandemics. To facilitate early treatment and help mitigate patient surge 
at emergency departments and clinics, distribution may require strategies such as fever 
clinics, nurse telephone triage consultation; and antiviral provision in pharmacies, schools, 
or other community settings. Efforts to educate clinicians and the public about the clinical 
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benefit of early antiviral treatment are vital, including those at high risk of influenza 
complications.
Although current understanding of influenza virus pathogenesis has advanced considerably 
since 1918, challenges remain in developing effective therapies for hospitalized patients with 
influenza, including those with severe complications. Influenza virus infection of the 
respiratory tract can trigger a dysregulated cytokine response, resulting in inflammatory 
tissue damage and increased alveolar capillary permeability; therefore, the potential of 
adjunctive therapies targeting the host response, including immunomodulators and anti-
inflammatory agents, has garnered attention. Immunotherapies for hospitalized influenza 
patients are in development, but demonstrating clinical benefit of these virus-targeted 
treatments in severe disease may be challenging without substantial reduction or blockade of 
the host inflammatory response. The use of systemic corticosteroids, particularly high doses 
for severely ill patients, has been associated with prolonged shedding of influenza virus and 
increased risk of ventilator-associated pneumonia, without survival benefit and no data from 
RCTs involving patients with influenza are available.
Critical care medicine was still a new specialty during the 1968 influenza A(H3N2) 
pandemic. The next pandemic in 2009 was no-table for its low overall global mortality and 
the contributions of advanced organ support and intensive care in the management of 
critically ill patients with acute respiratory distress syndrome (ARDS), multi organ failure, 
and sepsis triggered by influenza virus or secondary bacterial infection. However, clinical 
management of patients with influenza is not standardized, and no RCT data exist 
specifically from patients with influenza to guide optimal management of critically ill 
patients. Use of advanced organ support for critically ill patients with influenza (eg, low tidal 
volume ventilation, prone positioning, neuromuscular blockade, optimal fluid management, 
and extracorporeal membrane oxygenation [ECMO]) is based on data and principles for 
management of critical illness primarily due to other causes.7 Secondary bacterial infection, 
particularly pneumonia, contributed to critical and fatal illness during the 1918,1957,1968, 
and 2009 pandemics. Yet issues such as accurate diagnosis of invasive bacterial infection 
with seasonal influenza, antibiotic choice, timing of treatment de-escalation, and optimal 
duration of therapy remain unresolved.
During the 2009 influenza A(H1N1) pandemic, a monovalent vaccine became available in 
the United States only after the second wave had peaked. New technologies to expedite 
vaccine development and manufacturing are needed to improve the effectiveness of seasonal 
influenza vaccines, to prepare for the next pandemic virus, and to achieve progress toward 
universal vaccines that confer broad cross-protection. Despite major advances in patient care 
since 1918, and even with the development of more effective influenza vaccines and 
universal vaccines in the future, influenza epidemics and pandemics will continue to cause 
substantial morbidity and mortality worldwide and may overwhelm clinical care capacity–
particularly critical care capacity, especially in resource-constrained settings–without further 
improvements in influenza prevention and clinical management. Estimated mortality 
associated with the 2009 influenza A(H1N1) pandemic and recent influenza epidemics was 
highest in areas of the world with the least capacity for acute and intensive care. Building 
and strengthening clinical capacity is essential in low-resource and middle-income countries 
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and must incorporate infection prevention and control measures as well as access to critical 
care.
This year is not only the centennial of the 1918 pandemic, but also marks the 50th 
anniversary of the 1968 pandemic that introduced influenza A(H3N2) viruses into humans. 
Influenza A(H3N2) virus strains continue to circulate world-wide and predominated again 
during the 2017–2018 influenza season in the United States. The severity of the past season 
once more calls attention to the gaps that persist in the clinical management of patients with 
seasonal influenza. Ongoing prospective, multiyear, multi country, multiregional clinical 
research networks can serve as platforms for conducting randomized clinical adaptive trials 
studying interventions to inform the clinical management of influenza.8 Some have already 
been established,8 but wider global networks are needed to address this global disease. 
Existing networks should be expanded, new ones established, and most importantly, 
coordination prioritized. Key questions to address include (1) What is the optimal antiviral 
treatment (including dosing, duration, and possible combination antiviral treatment) for 
hospitalized non critically ill and critically ill patients with influenza? (2) What antibiotic 
regimens and durations of treatment are optimal for patients with influenza pneumonia and 
secondary bacterial infection? (3) What is the role and efficacy of immunomodulating 
therapy (including optimal dosing, timing of initiation, and duration) for hospitalized non 
critically ill and critically ill patients with influenza? (4) What advanced organ support 
strategies (eg, prone positioning, ECMO, conservative vs liberal fluid management) improve 
outcomes for patients with influenza-related critical illness? (5) Can biomarkers accurately 
predict development of severe disease in patients with influenza?
Advances in the clinical management of patients with seasonal influenza during annual 
epidemics will also prepare clinicians to respond better to the next influenza pandemic, 
whenever that may be.
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